ACBI3

ACBI3 : panKRAS Degrader (PROTAC)

Structure

Information

  • KRAS (Mutant:pan variants)
  • Degrader (PROTAC)
  • up to 100 nM

In Vitro Validations

Uniprot ID: P01116
Target Class: Kinase
Target SubClass: Ras Family
Potency: Kd
Potency Value: 6 nM
Potency Assay: SPR for ternary complex with VHL
PDB ID for probe-target interaction (3D structure): 8QU8 8QVU
Target aliases:
GTPase KRas, RASK2, KRAS2, KRAS, RASK_HUMAN, c-Ki- ...

DOI Reference: 10.1126/science.adm8684

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency assay, off target (cells): The degradation selectivity of ACBI3 was assessed by whole cell proteomics MS analysis of GP2d cells treated with ACBI3 or the inactive stereoisomer cis-ACBI3 (50 nM). HRAS (log2 fold change -0.0006, -logP 0.001) and NRAS (log2 fold change -0.12, -logP 0.52) levels are not significantly affected.
Potency assay, off target (cells): Proliferation inhibition data was assessed for 240 cancer cell lines for ACBI3
I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

ACBI3 is a very well characterized pan KRAS degrader, developed by leaders in the field of targeted protein degradation. Sparing HRAS and NRAS, this probe is useful for addressing specific KRAS mutants when others are not present in a cell line, or for the simultaneous degradation of multiple KRAS mutants. The substance is well optimized for use in cell-based experiments, but is not fully optimized for in vivo use. The authors have, however, provided detailed formulation methods which can be used to achieve acceptable exposure, making in vivo experiments possible.

(last updated: 10 Oct 2025 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

While there is strong evidence of KRAS degradation, ternary complex, and pathway inhibition, data supporting direct cellular engagement of KRAS was not provided.

(last updated: 13 Oct 2025 )